Gilteritinib (ASP2215)

For research use only.

Catalog No.S7754

10 publications

Gilteritinib (ASP2215) Chemical Structure

CAS No. 1254053-43-4

Gilteritinib (ASP2215) is a small-molecule FLT3/AXL inhibitor with IC50 values of 0.29 nM and 0.73 nM for FLT3 and AXL, respectively. It inhibits FLT3 at an IC50 value that was approximately 800-fold more potent than the concentration required to inhibit c-KIT (230 nM).

Size Price Stock Quantity  
RMB 1040.16 In stock
RMB 3497.67 In stock
RMB 7289.45 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Gilteritinib (ASP2215) has been cited by 10 publications

Purity & Quality Control

Choose Selective FLT3 Inhibitors

Biological Activity

Description Gilteritinib (ASP2215) is a small-molecule FLT3/AXL inhibitor with IC50 values of 0.29 nM and 0.73 nM for FLT3 and AXL, respectively. It inhibits FLT3 at an IC50 value that was approximately 800-fold more potent than the concentration required to inhibit c-KIT (230 nM).
FLT3 [1]
(Cell-free assay)
Axl [1]
(Cell-free assay)
0.29 nM 0.73 nM
In vitro

Gilteritinib demonstrates potent inhibitory activity against the internal tandem duplication (FLT3-ITD) and FLT3-D835Y point mutations in cellular assays using MV4-11 and MOLM-13 cells as well as Ba/F3 cells expressing mutated FLT3. Gilteritinib decreases the phosphorylation levels of FLT3 and its downstream targets in both cellular and animal models. Gilteritinib inhibits the activity of eight of the 78 tested kinases by over 50% at concentrations of either 1 nM (FLT3, LTK, ALK, and AXL) or 5 nM (TRKA, ROS, RET, and MER)[1]. Gilteritinib treatment for 48h results in an induction of apoptosis in MV4-11 cells as determined by an increase in annexin V-positive cells. Gilteritinib also decreases the expression of anti-apoptotic proteins such as MCL-1, BCL2L10, and survivin, which are reported to be important in chemotherapy sensitivity, following 24h treatment[2].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV4-11 cells MV3D[YxtKGO7Y3zlJIF{e2G7 Mor4NUwhOyxiMUCsJIFv\CB|MDDuUS=> MonjNlQhcA>? NX3hRXp2XGinIH3lZY4heHKxcH;yeIlwdiCxZjDNWlQuOTFiY3XscJMhcW5iR{GgdIhie2Vid3Xy[UB{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnZDDheEBocWy2ZYLpeIlvcWJiY3;uZ4VvfHKjdHnvcpMhd2ZiMzCoOlkvOCV9IGC8NE4xOSliYX7kJFExKG6PIDi3NE44LTtiUEywMlAxOSlw MmT1N|ExPjlyMUW=
MOLM-13 cells M4DocmFxd3C2b4Ppd{Bie3OjeR?= M{K0ZlEtKDNuIEGwMEA{OCxiYX7kJFExOCCwTR?= M3fJelQ5KGh? MX;zbYdvcW[rY3HueEBqdmO{ZXHz[ZMhcW5idHjlJJBmemOnboTh[4Uhd2ZiYX7u[ZhqdiCYLYDvd4l1cX[nIHPlcIx{KGG2IHPvcoNmdnS{YYTpc45{KG:oIEOwJI5OKCh|Mj6wKUkh[W6mIEGwNEBvVSBqNUKuOEUqKH[ncoP1d{Bkd262cn;sJEg1NjFnKR?= NHjhXXI{OTB4OUCxOS=>
32D/TKD cells MleySpVv[3Srb36gZZN{[Xl? NUHpSlFZPTBibl5CpC=> NFv0Xpo3KGh? NIDC[lFKdmirYnn0c44hd2ZidHjlJJBpd3OyaH;yfYxifGmxbjDv[kBCc3Rib36gWFMxQA>? NX\FXFdSOjl3MEe2OlA>
TF-1 cells M4[wdmZ2dmO2aX;uJIF{e2G7 MX:wMEAzOCxiOECsJFIxOCCjbnSgOVAxKG6P NFTvS2kyKGh? NYDmcYVy\2mudHXybZRqdmmkIHjhd{BidiCLQ{WwJIFo[Wmwc4Sge4lt\C22eYDlJIMuU2m2IH;mJFExOiCwTR?= M1fTWFI4QTB6OEix

... Click to View More Cell Line Experimental Data

Methods Test Index PMID
Western blot
p-STAT5 / STAT5 / p-AKT / AKT / p-ERK / ERK; 

PubMed: 28516360     

Immunoblot for phosphorylated AKT, ERK, and STAT5 in gilteritinib-treated MV4–11 cells. Blots from one study, which was done in triplicate, are shown.

p-c-kit / c-kit; 

PubMed: 27908881     

TF-1 cells were treated with increasing concentrations gilteritinib in RPMI/10% FBS for 1 hour. Immunoprecipitation and immunoblotting were performed to detect the phosphorylation status of c-Kit and total c-Kit.

p-FLT3(Y591) / FLT3; 

PubMed: 30344940     

Cells were treated with or without 10 nM gilteritinib, or midostaurin for 6 h, and immunoblotting was performed using the indicated antibodies.

28516360 27908881 30344940
In vivo In vivo, gilteritinib is distributed at high levels in xenografted tumors after oral administration. The decreased FLT3 activity and high intratumor distribution of gilteritinib translates to tumor regression and improved survival in xenograft and intra-bone marrow transplantation models of FLT3-driven AML. This antitumor activity is associated with a durable inhibition of phospho-FLT3 and phospho-STAT5. Furthermore, treatment with gilteritinib decreases the leukemic burden and prolongs survival in a mouse IBMT model. No overt toxicity is seen in mouse models treated with gilteritinib[1].


Cell Research:


- Collapse
  • Cell lines: MV4-11 cells
  • Concentrations: 0.1 nM, 1 nM, and 10 nM
  • Incubation Time: 2 h
  • Method:

    MV4-11 cells are treated with DMSO or increasing concentrations of gilteritinib for 2 hours. Immunoprecipitation and immunoblot for phosphorylated FLT3 and total FLT3 are performed.

    (Only for Reference)
Animal Research:


- Collapse
  • Animal Models: MV4-11 xenografted mice (Nude mice)
  • Dosages: 1 mg/kg, 6 mg/kg, and 10 mg/kg
  • Administration: oral
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (180.92 mM)
Water Insoluble
Ethanol '85 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 552.71


CAS No. 1254053-43-4
Storage powder
in solvent
Synonyms N/A

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04140487 Recruiting Drug: Azacitidine|Drug: Gilteritinib|Drug: Venetoclax Recurrent Acute Myeloid Leukemia|Recurrent Myelodysplastic Syndrome|Refractory Acute Myeloid Leukemia|Refractory Myelodysplastic Syndrome M.D. Anderson Cancer Center|National Cancer Institute (NCI) December 17 2019 Phase 1|Phase 2
NCT03730012 Recruiting Drug: gilteritinib|Drug: atezolizumab Acute Myeloid Leukemia (AML)|Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation Astellas Pharma Global Development Inc.|Astellas Pharma Inc June 19 2019 Phase 1|Phase 2
NCT03964038 Completed Drug: gilteritinib|Drug: gilteritinib mini tablet Healthy Volunteer Astellas Pharma Global Development Inc.|Astellas Pharma Inc May 21 2019 Phase 1
NCT03625505 Recruiting Drug: Venetoclax|Drug: Gilteritinib Acute Myeloid Leukemia (AML) AbbVie|Astellas Pharma Inc Genentech Inc. October 18 2018 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

FLT3 Signaling Pathway Map

Related FLT3 Products

Tags: buy Gilteritinib (ASP2215) | Gilteritinib (ASP2215) supplier | purchase Gilteritinib (ASP2215) | Gilteritinib (ASP2215) cost | Gilteritinib (ASP2215) manufacturer | order Gilteritinib (ASP2215) | Gilteritinib (ASP2215) distributor
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID